Literature DB >> 12419799

Human T-lymphotropic virus type I tax activates I-kappa B kinase by inhibiting I-kappa B kinase-associated serine/threonine protein phosphatase 2A.

De-Xue Fu1, Yu-Liang Kuo, Bao-Ying Liu, Kuan-Teh Jeang, Chou-Zen Giam.   

Abstract

I-kappa B kinase (IKK) is a serine/threonine kinase that phosphorylates I-kappa B alpha and I-kappa B beta and targets them for polyubiquitination and proteasome-mediated degradation. IKK consists of two highly related catalytic subunits, alpha and beta, and a regulatory gamma subunit, which becomes activated after serine phosphorylation of the activation loops of the catalytic domains. The human T-lymphotropic retrovirus type-I trans-activator, Tax, has been shown to interact directly with IKK gamma and activates IKK via a mechanism not fully understood. Here we demonstrate that IKK binds serine/threonine protein phosphatase 2A (PP2A), and via a tripartite protein-protein interaction, Tax, IKK gamma, and PP2A form a stable ternary complex. In vitro, PP2A down-regulates active IKK prepared from Tax-producing MT4 cells. In the presence of Tax, however, the ability of PP2A to inactivate IKK is diminished. Despite their interaction with IKK gamma, PP2A-interaction-defective Tax mutants failed to activate NF-kappa B. Our data support the notion that IKK gamma-associated PP2A is responsible for the rapid deactivation of IKK, and inhibition of PP2A by Tax in the context of IKK x PP2A x Tax ternary complex leads to constitutive IKK and NF-kappa B activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419799     DOI: 10.1074/jbc.M210631200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

Review 1.  Viral manipulation of DNA repair and cell cycle checkpoints.

Authors:  Mira S Chaurushiya; Matthew D Weitzman
Journal:  DNA Repair (Amst)       Date:  2009-05-26

Review 2.  Targeting protein serine/threonine phosphatases for drug development.

Authors:  Jamie L McConnell; Brian E Wadzinski
Journal:  Mol Pharmacol       Date:  2009-03-19       Impact factor: 4.436

3.  Evidence for NF-kappaB- and CBP-independent repression of p53's transcriptional activity by human T-cell leukemia virus type 1 Tax in mouse embryo and primary human fibroblasts.

Authors:  Akiko Miyazato; Sergey Sheleg; Hidekatsu Iha; Yan Li; Kuan-Teh Jeang
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 4.  Cell cycle regulation during viral infection.

Authors:  Sumedha Bagga; Michael J Bouchard
Journal:  Methods Mol Biol       Date:  2014

Review 5.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

6.  Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells.

Authors:  Mohd Minhajuddin; Kaiser M Bijli; Fabeha Fazal; Antonella Sassano; Keiichi I Nakayama; Nissim Hay; Leonidas C Platanias; Arshad Rahman
Journal:  J Biol Chem       Date:  2008-12-13       Impact factor: 5.157

Review 7.  Viruses associated with human cancer.

Authors:  Margaret E McLaughlin-Drubin; Karl Munger
Journal:  Biochim Biophys Acta       Date:  2007-12-23

Review 8.  Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses.

Authors:  Zhi-Ming Zheng
Journal:  Int J Biol Sci       Date:  2010-12-01       Impact factor: 6.580

9.  Regulation of HIV-1 transcription at 3% versus 21% oxygen concentration.

Authors:  Sharroya Charles; Tatyana Ammosova; Jessica Cardenas; Altreisha Foster; Jamie Rotimi; Marina Jerebtsova; Abisola A Ayodeji; Xiaomei Niu; Patricio E Ray; Victor R Gordeuk; Fatah Kashanchi; Sergei Nekhai
Journal:  J Cell Physiol       Date:  2009-11       Impact factor: 6.384

Review 10.  A new look at T cell receptor signaling to nuclear factor-κB.

Authors:  Suman Paul; Brian C Schaefer
Journal:  Trends Immunol       Date:  2013-03-07       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.